SCHEMBL2675944

SCHEMBL2675944

CCN(CC)CCn1cc(-c2cc(Oc3ccc4nc(NC(C)C5CCCCC5)sc4c3)ccn2)cn1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CSF1R P07333 14/20 0.37
▸ MET P08581 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ PDGFRB P09619 4/20 0.37
▸ PDGFRA P16234 4/20 0.37
▸ FLT3 P36888 4/20 0.37
▸ PI4KA P42356 2/20 0.37
▸ PI4KB Q9UBF8 2/20 0.37
▸ KIT P10721 2/20 0.37
▸ PIP5K1C O60331 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ TGFBR1 P36897 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675941 1.00 USP30 (0.38) USP30NPC1MAPTPKMRAB9A
SCHEMBL2676592 0.92 USP30 (0.40) USP30NPC1MAPTPKMRAB9A
SCHEMBL2676596 0.92 USP30 (0.40) USP30NPC1MAPTPKMRAB9A
SCHEMBL2676644 0.91 CSF1R (0.44) USP30NPC1MAPTPKMRAB9A
SCHEMBL2676648 0.91 CSF1R (0.44) USP30NPC1MAPTPKMRAB9A
SCHEMBL14396772 0.90 CSF1R (0.39) USP30NPC1MAPTPKMRAB9A
SCHEMBL2677406 0.90 CSF1R (0.38) USP30NPC1MAPTPKMRAB9A
SCHEMBL4373929 0.90 CSF1R (0.38) USP30NPC1MAPTPKMRAB9A
SCHEMBL2675565 0.89 CSF1R (0.39) USP30NPC1MAPTPKMRAB9A
SCHEMBL2675566 0.89 CSF1R (0.39) USP30NPC1MAPTPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US claimed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2010-11-04 — — US disclosed
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling CSF1R, CSF3R, FLT3 USP30 3387/4885NPC1 3788/4885MAPT 1077/4885
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling CSF1R, CSF3R, FLT3 USP30 3387/4885NPC1 3788/4885MAPT 1077/4885
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING CSF1R, CSF3R, FLT3 USP30 3387/4885NPC1 3788/4885MAPT 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback